One study reported that concurrent increased expression of ADRB2 and PTGS2 in ovarian cancer was associated with poor survival (37), suggesting activation of this axis should be explored as a biological pathways driving disease spread, leading to residual disease. This evidence concerns the gene ADRB2 and ovarian carcinoma.